Statement: In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years.
Primary_evidence: Outcome Measurement:    Recurrence-free Survival   2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)   Time frame: 5 years Results 1:    Arm/Group Title: Ketorolac 30 mg   Arm/Group Description: Active drug to be compared with placebo   Ketorolac 30 mg IV   Overall Number of Participants Analyzed: 96   Measure Type: Count of Participants   Unit of Measure: Participants  80  83.3% Results 2:    Arm/Group Title: NaCl 0.9% 3mL   Arm/Group Description: Ketorolac 30 mg IV   Overall Number of Participants Analyzed: 107   Measure Type: Count of Participants   Unit of Measure: Participants  96  89.7%